William Blair Reiterates “Outperform” Rating for Simulations Plus (NASDAQ:SLP)

Simulations Plus (NASDAQ:SLP)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a note issued to investors on Tuesday,RTT News reports.

SLP has been the topic of several other reports. Wall Street Zen upgraded shares of Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday, April 28th. JMP Securities reiterated a “market perform” rating on shares of Simulations Plus in a research note on Wednesday, June 18th. KeyCorp lowered shares of Simulations Plus from an “overweight” rating to a “sector weight” rating in a research note on Tuesday. BTIG Research cut their price target on shares of Simulations Plus from $41.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, July 7th. Finally, Stephens cut their price target on shares of Simulations Plus from $28.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Simulations Plus currently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Simulations Plus Trading Down 0.5%

Shares of SLP stock opened at $12.91 on Tuesday. The company’s 50-day moving average price is $23.80 and its 200-day moving average price is $28.08. The stock has a market cap of $259.62 million, a price-to-earnings ratio of -4.10 and a beta of 0.83. Simulations Plus has a twelve month low of $12.85 and a twelve month high of $44.27.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Monday, July 14th. The technology company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.19. The firm had revenue of $20.36 million for the quarter, compared to analyst estimates of $22.83 million. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 10.65%. Simulations Plus’s revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.27 EPS. As a group, equities research analysts predict that Simulations Plus will post 1.09 EPS for the current year.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the sale, the director directly owned 3,344,157 shares in the company, valued at approximately $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 19.40% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLP. Jones Financial Companies Lllp boosted its holdings in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after purchasing an additional 427 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Simulations Plus by 4.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 143,253 shares of the technology company’s stock valued at $3,995,000 after purchasing an additional 6,418 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in Simulations Plus in the fourth quarter valued at approximately $719,000. AlphaQuest LLC boosted its holdings in Simulations Plus by 502.9% in the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after purchasing an additional 2,243 shares in the last quarter. Finally, Natixis Advisors LLC acquired a new position in Simulations Plus in the fourth quarter valued at approximately $288,000. 78.08% of the stock is owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.